Practical use of rectal medications in palliative care

Journal of Pain and Symptom Management

Volumn 11, Issue 6, 1996, Pages 378-387

  Warren, Duane E ^a,b,c  

^a St Lawrence Hospital   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Pharm Group Practice Associates PC   (United States)

Author keywords

administration, rectal; analgesics, opioid; anti inflammatory agents, nonsteroidal; Drug administration, rectal; instillation, rectal; palliative care, drug therapy; palliative treatment; terminal care

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; DROPERIDOL; IBUPROFEN; LORAZEPAM; METHADONE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NAPROXEN; OPIATE; OXYCODONE; VALPROIC ACID;

CANCER PALLIATIVE THERAPY; DRUG EFFECT; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; HUMAN; RECTAL DRUG ADMINISTRATION; REVIEW; TERMINAL CARE; TERMINAL DISEASE; VASCULARIZATION;

EID: 0029950117     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/0885-3924(96)00012-7     Document Type: Review

References (37)

1. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990;5:83-93.
2. Patt RB. Cancer pain. Philadelphia: JB Lippincott, 1993.
3. van Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 1991;21:11-26, 110-128.
4. Kaiko RF, Cronin C, Healy N, PavJ, et al. Bioavailability of rectal and oral MS Contin [Abstract]. Oncol Nurs Forum 1989;16(suppl 2):183.
5. Moolenaar F, Yska JP, Visser J, et al. Drastic improvement in the rectal absorption profile of morphine in man. Eur J Clin Pharmacol 1985;29: 119-121.
6. Maloney CM, Kesner RK, Klein G, Bockenstette J. The rectal administration of MS Contin: clinical implications of use in end stage cancer. Am J Hosp Care 1989;6:34-35.
7. Grauer PA, Bass J, Wenzel E, Wheeler W, Shepard KV. An evaluation of the analgesic effect of Oramorph SR tablets when administered rectally or vaginally in patients with terminal cancer [Abstract]. Proc Annu Meet Am Soc Clin Oncol 1992;11:A1392.
8. Kaiko RF, Fitzmartin RD, Thomas GB, Goldenheim PD. The bioavailability of morphine in controlled-release 30mg tablets per rectum compared with immediate-release 30mg rectal suppositories and controlled-release 30mg oral tablets. Pharmacotherapy 1992;12:107-113.
9. Babul N, Darke AC, Anslow JA, Krishnamurthy TN. Pharmacokinetics of two novel rectal controlled-release morphine formulations. J Pain Symptom Manage 1992;7:400-405.
10. Osborne R, Thompson P Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992;34:130-138.
11. Hanna MH, Peat JF, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-t-glucuronide: comparison with morphine. Br J Anaesth 1990;64:547-555.
12. Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992;51:442-451.
13. Wilkinson TJ, Robinson BA, Begg EJ, Duffull SB, Ravenscroft PJ, Schneider JJ. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992;31:251-254.
14. Babul N, Darke AC. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther 1993;54:286-292.
15. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992;14:479-484.
16. Bruera E, Schoeller T, Fainsinger RL, Kastelan C. Custom-made suppositories of methadone for severe cancer pain. J Pain Symptom Manage 1992;7:372-374.
17. Calvo MV, Lanao JM, Cominguez-Gil A. Bioavailability of rectally administered naproxen. Int J Pharmaceutics 1987;38:117-122.
18. Maunuksela EL, Rhyanen P, Janhunen L. Efficacy of rectal ibuprofen in controlling postoperative pain in children. Can J Anaesth 1992;39:226-230.
19. Eller MG, Wright C, Della-Coletta AA. Absorption kinetics of rectally and orally administered ibuprofen. Biopharm Drug Dispos 1989;10:269-278.
20. Becker P, Jamez R, Weber M. Concentrations plasmatiques de quelques anti-inflammatoires non-steroidiens, après administration rectale unique chez le volontaire sain. Acta Therapeutica 1983;9:333-343.
21. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical practice guideline no. 9. Agency for Health Care Policy and Research (AHCPR) publication no. 94-0592. Rockville, MD: AHCPR, U.S. Department of Health and Human Services, Public Health Service March
22. Vergin H, Krammer R, Nitsche V, Miczka M, Strobel K, Schimmel H. Bioavailability and pharmacokinetics of rectally administered metoclopramide. Arznemittelforschung (Drug Res) 1990;40:679-683.
23. Hardy F, Warrington PS, MacPherson JS, et al. A pharmacokinetic study of high-dose metoclopramide suppositories. J Clin Pharm Ther 1990;15:21-24.
24. Gupta SK, Southam M, Swang S. Pharmacokinetics of droperidol in healthy volunteers following intravenous infusion and rectal administration from an osmotic drug delivery module. Pharm Res 1992; 9:694-696.
25. Graves NM, Griel RL, Sones-Saete C, Cloyd JC. Relative bioavailability of rectally administered carbamazepine suspension in humans. Epilepsia 1985; 26:429-433.
26. Neuvonen PJ, Tokola O. Bioavailability of rectally administered carbamazepine mixture. Br J Clin Pharmacol 1987;24:839-841.
27. Storey P, Trumble M. Rectal doxepin and carbamazepine therapy in patients with cancer [Letter]. N Engl J Med 1992;327:1318-1319.
28. Yoshiyama Y, Nakano S, Ogawa N. Chronopharmacokinetic study of valproic acid in man: comparison of oral and rectal administration. J Clin Pharmacol 1989;29:1048-1052.
29. Kanazawa O, Sengoku A, Kawai I. Treatment of childhood epilepsy with rectal valproate: case reports and pharmacokinetic study. Brain Dev 1987; 9:615-620.
30. Fuerst R, Graves N, Kriel R, Olson R. Absorption and safety of rectally administered phenytoin. Eur J Drug Metab Pharmacokinet 1988;13:257-260.
31. Remy C, Jourdil N, Villemain D, Favel P, Genton P. Intrarectal diazepam in epileptic adults. Epilepsia 1992;33:353-358.
32. Hansen HC, Harboe H, Drenck NE. Local irritation after administration of diazepam in a rectal solution. Br J Anaesth 1989;63:287-289.
33. Graves NM, Kriel RL, Jones-Saete C. Bioavailability of rectally administered lorazepam. Clin Neuropharmacol 1987;10:555-559.
34. Malinovsky JM, Lejus C, Servin F, et al. Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. Br J Anaesth 1993; 70:617-620.
35. Wong L, McQueen KD. Midazolam routes of administration. DICP 1991;25:476-477.
36. Klosterskov Jensen P, Abild K, Nohr Poulsen M. Serum concentration of clonazepam after rectal administration. Acta Neurol Scand 1983;68:417-420.
37. Drug Information '95, American Hospital Formulary Service. Bethesda, MD: American Society of Health-System Pharmacists.